World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
33761
World Ranking
15901
National Ranking
8002

Kenneth C. Kalunian publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kenneth C. Kalunian sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 296 publications — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kenneth C. Kalunian D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kenneth C. Kalunian sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kenneth C. Kalunian is affiliated with the University of California, San Diego in the United States and has made significant contributions to medical research, particularly in the field of rheumatology. Their work primarily focuses on systemic lupus erythematosus (SLE), monoclonal and polyclonal antibodies, and related autoimmune conditions.

Kalunian's research encompasses a broad spectrum of topics within medicine, with a strong emphasis on:

  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Atherosclerosis and Cardiovascular Diseases
  • Liver Diseases and Immunity
  • Renal Diseases and Glomerulopathies
  • Rheumatoid Arthritis Research and Therapies
  • T-cell and B-cell Immunology

Their scientific output falls predominantly within the main field of Medicine and more specifically within subfields such as Rheumatology, Immunology, Radiology, Nuclear Medicine and Imaging, Genetics, and Pathology and Forensic Medicine. Their research articles have appeared in several leading journals and publication venues, including:

  • Annals of the Rheumatic Diseases
  • Lupus Science & Medicine
  • UNC Libraries
  • Arthritis Care & Research
  • The Journal of Rheumatology

Recent publications by Kenneth C. Kalunian illustrate their focus on clinical trials and therapeutic interventions for lupus and related autoimmune diseases. Selected recent papers include:

  • "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)" (2023, The Lancet)
  • "A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus" (2022, Arthritis & Rheumatology)
  • "Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials" (2022, Annals of the Rheumatic Diseases)
  • "Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus" (2022, New England Journal of Medicine)
  • "Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus" (2022, New England Journal of Medicine)

Collaboration is a notable aspect of Kalunian's research career, counting frequent co-authors such as Diane L. Kamen, Michelle Petri, Daniel J. Wallace, Anca Askanase, and Ian N Bruce. These collaborative relationships further reflect the extensive engagement in the field of lupus and autoimmune disorders.

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

    Dafna Gladman;Ellen Ginzler;Charles Goldsmith;Paul Fortin

  • Combined oral contraceptives in women with systemic lupus erythematosus

    Michelle Petri;Mimi Y. Kim;Kenneth C. Kalunian;Jennifer Grossman

  • Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

    Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth

  • The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.

    Dafna D. Gladman;Murray B. Urowitz;Charles H. Goldsmith;Paul Fortin

  • The immune cell landscape in kidneys of patients with lupus nephritis

    Arnon Arazi;Deepak A Rao;Celine C Berthier;Anne Davidson

  • The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial

    Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian

  • A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

    Gary S. Hoffman;Maria C. Cid;David B. Hellmann;Loic Guillevin

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N Bruce;Aidan G O'Keeffe;Vernon Farewell;John G Hanly

  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

    Daniel J Wallace;Richard A Furie;Yoshiya Tanaka;Kenneth C Kalunian

  • Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

    Maureen McMahon;Jennifer Grossman;John FitzGerald;Erika Dahlin-Lee

  • Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Munther Khamashta;Joan T Merrill;Victoria P Werth;Victoria P Werth;Richard Furie

  • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

    Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis

  • Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

    Richard A Furie;Eric F Morand;Ian N Bruce;Susan Manzi

  • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

    Daniel J Wallace;Kenneth Kalunian;Michelle A Petri;Vibeke Strand

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

  • A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

    Kenneth C Kalunian;Joan T Merrill;Romeo Maciuca;Jacqueline M McBride

  • Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

    J. G. Hanly;M. B. Urowitz;J. Sanchez-Guerrero;S. C. Bae

  • Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus.

    B P Tsao;R M Cantor;K C Kalunian;C J Chen

Frequent Co-Authors

Joan T. Merrill
Joan T. Merrill Oklahoma Medical Research Foundation
Daniel J. Wallace
Daniel J. Wallace Cedars-Sinai Medical Center
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
Caroline Gordon
Caroline Gordon University of Birmingham
Ian N. Bruce
Ian N. Bruce University of Manchester
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Murray B. Urowitz
Murray B. Urowitz University of Toronto
Paul R. Fortin
Paul R. Fortin Université Laval
David A. Isenberg
David A. Isenberg University College London
Susan Manzi
Susan Manzi Allegheny Health Network

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in healthcare doesn’t always mean pursuing a traditional path to becoming a physician. There are multiple online degree options and career routes available for those interested in working in the healthcare sector.

For professionals with a non-nursing bachelor’s degree looking to break into nursing, non nursing bachelor's to msn online programs offer a fast track to earning an advanced degree and entering the field. If you’re concerned about entrance exams, there are also nursing school without teas test requirements, making the application process more accessible.

Some prospective students seek what is the easiest nursing program to get into to help launch their careers more quickly or with fewer hurdles. For those interested in roles related to healthcare administration, exploring accredited medical billing and coding schools online with financial aid can open doors to a stable, in-demand field.

Whether you’re aiming for a patient-facing or administrative role, many online options make it easier to begin a healthcare career on your terms.

Best Scientists Citing Kenneth C. Kalunian

Trending Scientists